Filing Flows › Comparisons › TCRX vs PRME
TScan Therapeutics vs Prime Medicine: TCRX and PRME compared
TScan Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $838K for Prime Medicine (Q4 2025). Prime Medicine is growing faster (-62% against -66% a year earlier).
Where the money goes: TCRX and PRME
TScan Therapeutics (TCRX) · Q2 2026
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
Prime Medicine (PRME) · Q4 2025
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.
| TScan Therapeutics (TCRX) | Prime Medicine (PRME) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2025 |
| Revenue | $1.1M | $838K |
| Revenue growth, Y/Y | -66% | -62% |
| Operating margin | n/m | n/m |
| Net earnings | −$30.4M | −$46.1M |
| Operating cash flow | −$27.5M | −$37.3M |
Questions
Which is bigger, TScan Therapeutics or Prime Medicine?
TScan Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $838K for Prime Medicine (Q4 2025).
Is TScan Therapeutics or Prime Medicine growing faster?
Prime Medicine is growing faster (-62% against -66% a year earlier).
More: TScan Therapeutics earnings · how TScan Therapeutics makes money · Prime Medicine earnings · how Prime Medicine makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-K filed Mar 3, 2026). Fiscal quarters can end on different dates. Not investment advice.